UBS Group
ROIV icon

UBS Group’s Roivant Sciences ROIV Stock Holding History

UBS Group’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$618M Sell
17,466,641
-5,152,831
-23% -$152M 0.08% 232
2026
Q1 		$627M Buy
22,619,472
+4,228,680
+23% +$109M 0.09% 210
2025
Q4 		$399M Buy
18,390,792
+15,645,836
+570% +$309M 0.06% 292
2025
Q3 		$41.5M Sell
2,744,956
-2,348,112
-46% -$29.1M 0.01% 1820
2025
Q2 		$57.4M Sell
5,093,068
-1,704,135
-25% -$18.5M 0.01% 1391
2025
Q1 		$68.6M Buy
6,797,203
+1,507,429
+28% +$16.3M 0.01% 1190
2024
Q4 		$62.6M Buy
5,289,774
+4,779,042
+936% +$56.5M 0.01% 1259
2024
Q3 		$5.89M Buy
510,732
+16,383
+3% +$187K ﹤0.01% 2905
2024
Q2 		$5.23M Sell
494,349
-43,248
-8% -$474K ﹤0.01% 2842
2024
Q1 		$5.67M Buy
537,597
+303,708
+130% +$3.27M ﹤0.01% 2840
2023
Q4 		$2.63M Buy
233,889
+3,543
+2% +$34.5K ﹤0.01% 3519
2023
Q3 		$2.69M Sell
230,346
-148,704
-39% -$1.68M ﹤0.01% 3157
2023
Q2 		$3.82M Buy
379,050
+371,480
+4,907% +$3.32M ﹤0.01% 2849
2023
Q1 		$55.9K Sell
7,570
-153,442
-95% -$1.26M ﹤0.01% 6369
2022
Q4 		$1.29M Buy
+161,012
New +$896K ﹤0.01% 3833

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's ROIV Position: Q2 2026 in Review

UBS Group reduced its Roivant Sciences (ROIV) stake by 23% in Q2 2026, selling an estimated $152M and leaving 17,466,641 shares worth $618M. The position accounts for 0.08% of the portfolio, ranked #232.

UBS Group first reported a position in ROIV in Q4 2022 and has held it in 15 quarters since. The position peaked at $627M in Q1 2026. 497 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • UBS Group held 17,466,641 shares of Roivant Sciences worth $618M as of Q2 2026.
  • UBS Group sold 5,152,831 Roivant Sciences shares in Q2 2026, an estimated $152M.
  • Roivant Sciences made up 0.08% of UBS Group's portfolio in Q2 2026, its #232 holding.
  • UBS Group first reported a position in Roivant Sciences in Q4 2022 and has held it in 15 quarters since.
  • UBS Group's Roivant Sciences position peaked at $627M in Q1 2026.
  • 497 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.